There’s no question that drug development is a risky endeavor with scientific, clinical, and commercial risk. Patients and society value advances in science that help people get well, stay healthy, and avoid more costly or burdensome settings of care. Policy choices have consequences, and they can either encourage innovation in tomorrow’s cures, or signal a belief that "we don't need any new treatments" and incentivize capital to invest elsewhere. The United States has been the world leader in innovation – but that isn’t an inalienable right. Session speakers will look to answer the following questions: What does the latest research reveal about the impact US policies like the Inflation Reduction Act have on investors? What can we learn from the impact of past policy choices in Europe or China? What should US leaders and policymakers know now?